InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,244.80
(
1.57%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.00%
)
Bitcoin
63,024.04
(
-1.12%
)
Post# of 251621
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119499
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: floblu14 post# 132597

Tuesday, 06/25/2013 9:34:31 AM

Tuesday, June 25, 2013 9:34:31 AM

Post# of 251621
USPTO issues sialylation patent licensed to MNTA:

http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-issuance-u-123000304.html

Momenta Pharmaceuticals…today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,470,318, entitled "Polypeptides With Enhanced Anti-inflammatory and Decreased Cytotoxic Properties and Related Methods," to The Rockefeller University. Momenta is the exclusive licensee of the patent. The patent claims methods of inhibiting inflammation using intravenous immunoglobulin (IVIG)-derived, sialylated Fc regions and expires in 2028.

This is the IP protection MNTA needed to continue pursuing the sialylated-IVIG program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up